id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-1351-0005,FDA,FDA-2021-N-1351,"References 2 - Eastern Research Group, Inc. (2003), ‘‘The Pharmaceutical Labeling Revisions Cost Model’’",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:19Z,,0,0,09000064851ea766
FDA-2021-N-1351-0004,FDA,FDA-2021-N-1351,References 1 - HIPAA for Professionals,Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:13Z,,0,0,09000064851ea765
FDA-2021-N-1351-0008,FDA,FDA-2021-N-1351,"References 5 - RAND (2004), ""The Costs and Benefits of Moving to the ICD-10 Code Sets""",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:46Z,,0,0,09000064851ea769
FDA-2021-N-1351-0006,FDA,FDA-2021-N-1351,"References 3 - RTI International (2015), ‘‘2014 FDA
Labeling Cost Model’’",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:25Z,,0,0,09000064851ea767
FDA-2021-N-1351-0007,FDA,FDA-2021-N-1351,"References 4 - FDA, Preliminary Regulatory Impact Analysis, ‘‘Revising the National Drug Code Format and Drug Label Barcode Requirements""",Supporting & Related Material,Background Material,2022-07-27T04:00:00Z,2022,7,,,2022-07-27T19:08:32Z,,0,0,09000064851ea768
FDA-2021-N-1351-0001,FDA,FDA-2021-N-1351,Revising the National Drug Code Format and Drug Label Barcode Requirements,Proposed Rule,Advance Notice of Proposed Rulemaking (ANPRM),2022-07-25T04:00:00Z,2022,7,2022-07-25T04:00:00Z,2022-11-23T04:59:59Z,2022-12-17T02:00:33Z,2022-15414,0,0,09000064851e55bd